Literature DB >> 24777896

Effect of tumor cells and tumor microenvironment on NK-cell function.

Massimo Vitale1, Claudia Cantoni, Gabriella Pietra, Maria Cristina Mingari, Lorenzo Moretta.   

Abstract

The ability of tumors to manage an immune-mediated attack has been recently included in the "next generation" of cancer hallmarks. In solid tumors, the microenvironment that is generated during the first steps of tumor development has a pivotal role in immune regulation. An intricate net of cross-interactions occurring between tumor components, stromal cells, and resident or recruited immune cells skews the possible acute inflammatory response toward an aberrant ineffective chronic inflammatory status that favors the evasion from the host's defenses. Natural killer (NK) cells have powerful cytotoxic activity, but their activity may be eluded by the tumor microenvironment. Immunosubversion, immunoediting or immunoselection of poorly immunogenic tumor cells and interference with tumor infiltration play a major role in evading NK-cell responses to tumors. Tumor cells, tumor-associated fibroblasts and tumor-induced aberrant immune cells (i.e. tolerogenic or suppressive macrophages, dendritic cells (DCs) and T cells) can interfere with NK-cell activation pathways or the complex receptor array that regulate NK-cell activation and antitumor activity. Thus, the definition of tumor microenvironment-related immunosuppressive factors, along with the identification of new classes of tissue-residing NK-like innate lymphoid cells, represent key issues to design effective NK-cell-based therapies of solid tumors.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Inflammation; NK cells; Tumor escape

Mesh:

Year:  2014        PMID: 24777896     DOI: 10.1002/eji.201344272

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  124 in total

1.  Identifying prostate cancer and its clinical risk in asymptomatic men using machine learning of high dimensional peripheral blood flow cytometric natural killer cell subset phenotyping data.

Authors:  Simon P Hood; Georgina Cosma; A Graham Pockley; Gemma A Foulds; Catherine Johnson; Stephen Reeder; Stéphanie E McArdle; Masood A Khan
Journal:  Elife       Date:  2020-07-28       Impact factor: 8.140

2.  Immunomodulatory Magnetic Microspheres for Augmenting Tumor-Specific Infiltration of Natural Killer (NK) Cells.

Authors:  Wooram Park; Andrew C Gordon; Soojeong Cho; Xiaoke Huang; Kathleen R Harris; Andrew C Larson; Dong-Hyun Kim
Journal:  ACS Appl Mater Interfaces       Date:  2017-04-17       Impact factor: 9.229

3.  CD8+ T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy.

Authors:  Jillian Rosenberg; Jun Huang
Journal:  Curr Opin Chem Eng       Date:  2017-12-14       Impact factor: 5.163

4.  Engineered immune cells as highly sensitive cancer diagnostics.

Authors:  Amin Aalipour; Hui-Yen Chuang; Surya Murty; Aloma L D'Souza; Seung-Min Park; Gunsagar S Gulati; Chirag B Patel; Corinne Beinat; Federico Simonetta; Ivana Martinić; Gayatri Gowrishankar; Elise R Robinson; Eamon Aalipour; Zahra Zhian; Sanjiv S Gambhir
Journal:  Nat Biotechnol       Date:  2019-03-18       Impact factor: 54.908

5.  IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid.

Authors:  D Croxatto; S Martini; L Chiossone; F Scordamaglia; C F Simonassi; L Moretta; M C Mingari; P Vacca
Journal:  Oncoimmunology       Date:  2017-02-17       Impact factor: 8.110

6.  Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells.

Authors:  Gabriele Gamerith; Arno Amann; Bettina Schenk; Thomas Auer; Hans Lentzen; Dirk O Mügge; Katharina M Cima; Judith Löffler-Ragg; Wolfgang Hilbe; Heinz Zwierzina
Journal:  Oncol Lett       Date:  2017-08-31       Impact factor: 2.967

7.  Efficacy and Safety of Intralesional Xantinol Nicotinate in the Treatment of Various Stages of Oral Submucous Fibrosis.

Authors:  Udita Singh
Journal:  J Clin Diagn Res       Date:  2016-10-01

Review 8.  Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy.

Authors:  Huang Zhu; Yi-Shin Lai; Ye Li; Robert H Blum; Dan S Kaufman
Journal:  Stem Cells       Date:  2018-01-03       Impact factor: 6.277

Review 9.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675

Review 10.  Overview of current immunotherapeutic strategies for glioma.

Authors:  Anda-Alexandra Calinescu; Neha Kamran; Gregory Baker; Yohei Mineharu; Pedro Ricardo Lowenstein; Maria Graciela Castro
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.